Insider filing · LGND
John L Lamattina
Director
profile →
Ligand Pharmaceuticals Incorporated
LGND · Healthcare · 36 filings in 24 months
ticker →
John L Lamattina sold $859K of Ligand Pharmaceuticals Incorporated (LGND)
Executed Nov 7 2025, disclosed Nov 12 2025, 5 days later.
Value, as filed
$859K
4,179 sh across 2 lots
Executed
Nov 7 2025
the trade date, as filed
Disclosed
Nov 12 2025
5 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JLJohn L Lamattina (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales, 1 filed past the two-business-day deadline), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.0M of LGND (4,102 sh across 2 lots, as filed), executed Jun 10.
The name
LGNDHealthcare · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by John L Lamattina in LGND
LGNDSALE
Ligand Pharmaceuticals Incorporated
$1.0M4,102 sh across 2 lots
Exec Jun 10
Filed Jun 12 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $434K
2,161 sh × $200.76
Exec Mar 6
Filed Mar 31 · 5:30 PM ET † LGNDSALE Ligand Pharmaceuticals Incorporated $298K
2,406 sh × $123.65
Exec Nov 27 2024
Filed Dec 2 2024 · 5:30 PM ET